ERCC2 Asp312Asn/Lys751Gln基因多态性与晚期非小细胞肺癌铂类药物化疗敏感性相关性的临床观察  

System evaluation of ERCC2Asp312Asn/Lys751Gln gene polymorphism with advanced non-small cell lung cancer with platinum chemotherapy drugs sensitivity correlation

作　　者：谢晓燕 李超 敬梅 宋昀 李双双 XIE Xiao-yan;LI Chao;JING Mei(Department of Respiratory Medicine,Air Force 986 Hospital,Xi'an Shaanxi 710054,China;Department of Geriatrics,Navy Special Medical Center,Shanghai 200052,China)

机构地区：[1]空军第986医院呼吸科,陕西西安710054 [2]海军特色医学中心老年医学科,上海200052

出　　处：《临床和实验医学杂志》2019年第20期2190-2193,共4页Journal of Clinical and Experimental Medicine

基　　金：陕西省社会发展科技攻关项目(编号:2015SF213)

摘　　要：目的观察和评价切除修复交叉互补基因2(ERCC2)Asp312Asn/Lys751Gln基因多态性与晚期非小细胞肺癌(NSCLC)对铂类药物化疗敏感性的相关性。方法回顾性分析2017年4月至2018年12月空军第986医院和海军特色医学中心收治的以铂类药物为主要化疗方案的76例NSCLC患者。应用基因芯片方法检测患者的ERCC2 Asp312Asn和Lys751Gln基因型,比较不同基因型与化疗疗效的关系。结果76例患者化疗总有效率为28.95%(22/76)。ERCC2 Asp312Asn基因型和Lys751Gln基因型分布均符合hardy-weinberg平衡,表明该组病例具有群体代表性。76例NSCLC患者中,ERCC2 Asp312Asn的Asp/Asp、Asp/Asn基因型频率分别为94.74%和5.26%;Lys751Gln的Lys/Lys、Lys/Gln基因型的频率分别为88.16和11.84%,均未检测到2个位点的突变纯合基因型。ERCC2 Asp312Asn和Lys751Gln基因型在化疗有效患者和无效患者之间的分布无统计学差异(P>0.05)。结论ERCC2 Asp312Asn和Lys751Gln单核苷酸多态性与晚期NSCLC对铂类药物化疗敏感性无关。Objective To observe and evaluate the correlation between ERCC2 Asp312Asn/Lys751Gln gene polymorphism and platinum sensitivity in advanced non-small cell lung cancer(NSCLC).Methods A retrospective analysis was conducted on 76 NSCLC patients treated in 986 Air Force Hospital from April 2017 to December 2018 with platinum drugs as the main chemotherapy regimen.ERCC2 Asp312Asn and Lys751Gln genotypes were detected by gene chip method,and the relationship between different genotypes and chemotherapy efficacy was analyzed.Results The total effective rate of chemotherapy in 76 patients was 28.95%(22/76).The distribution of ERCC2 Asp312Asn genotype and Lys751Gln genotype accorded with Hardy-Weinberg equilibrium,which indicated that the case group was representative of the population.In 76 NSCLC patients,the frequency of ASP/Asp and Asp/Asn genotypes of ERCC2 Asp312Asn was 94.74%and 5.26%respectively,while the frequency of Lys/Lys and Lys/Gln genotypes of Lys751 Gln was 88.16 and 11.84%respectively,and no homozygous mutations were detected at two loci.There was no significant difference in the distribution of ERCC2 Asp312Asn and Lys751Gln genotypes between patients with effective and ineffective chemotherapy(P>0.05).Conclusion ERCC2 Asp312Asn and Lys751Gln single nucleotide polymorphisms are not associated with the sensitivity of advanced NSCLC to platinum drugs.

关 键 词：晚期非小细胞肺癌 ERCC2 基因多态性 铂类药物 化疗敏感性 

分 类 号：R73[医药卫生—肿瘤]